Lesson plan

Gemlapodect

Gemlapodect ( , ; developmental code name NOE-105) is a phosphodiesterase PDE10A inhibitor which is under development for the treatment of Tourette's syndrome and speech disorders. It is taken orally. The drug is thought to work by modulating dopaminergic signaling in the striatum through PDE10A inhibition in medium spiny neurons. Gemlapodect was originated by Roche and is under development by Noema Pharma. As of September 2025, it is in phase 2 clinical trials for both Tourette's syndrome and speech disorders.

Back to article

Article summary

Gemlapodect ( , ; developmental code name NOE-105) is a phosphodiesterase PDE10A inhibitor which is under development for the treatment of Tourette's syndrome and speech disorders. It is taken orally. The drug is thought to work by modulating dopaminergic signaling in the striatum through PDE10A inhibition in medium spiny neurons. Gemlapodect was originated by Roche and is under development by Noema Pharma. As of September 2025, it is in phase 2 clinical trials for both Tourette's syndrome and speech disorders.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.